Related Experiment Video
Updated: Jan 23, 2026

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial
Nicole J van Steijn1, Isabel S Blommestijn1, Sebastiaan Blok2
1Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; Cardiology Centers of the Netherlands, Utrecht, the Netherlands.
Smartwatch screening significantly increased new onset atrial fibrillation (AF) detection in high-stroke-risk patients over six months. This remote monitoring approach proved more effective than standard care for identifying this common arrhythmia.
Area of Science:
- Cardiology
- Digital Health
- Preventive Medicine
Background:
- Atrial fibrillation (AF) is a leading cause of stroke, often undetected due to its asymptomatic and paroxysmal nature.
- Wearable technology offers a scalable, noninvasive method for screening cardiac arrhythmias like AF.
- Early detection of AF is crucial for implementing timely stroke prevention strategies.
Purpose of the Study:
- To evaluate the efficacy of remote smartwatch-based screening for detecting new-onset atrial fibrillation (AF).
- To compare the AF detection rate in patients at elevated stroke risk using smartwatch monitoring versus standard care.
- To assess the role of wearable technology in improving the diagnosis of AF in a high-risk population.
Main Methods:
- A prospective, multicenter randomized controlled trial involving 437 patients aged 65+ with elevated stroke risk (CHA₂DS₂-VASc ≥2 men, ≥3 women).
- Participants were randomized to either 6-month smartwatch monitoring (photoplethysmography and ECG) or standard care.
- New onset AF was confirmed via remote ECG review within 24 hours, defined as an episode lasting ≥30 seconds.
Main Results:
- New onset AF was detected in 9.6% of the smartwatch intervention group versus 2.3% in the standard care group (risk difference: 7.3%).
- The smartwatch group showed a significantly higher detection rate (P = 0.001) with a hazard ratio of 4.40.
- Several asymptomatic AF episodes were identified exclusively in the smartwatch group, highlighting its utility in detecting silent arrhythmias.
Conclusions:
- Six-month smartwatch-based screening significantly enhances the detection of new-onset atrial fibrillation in high-risk patients compared to standard care.
- Remote monitoring with smartwatches is an effective strategy for improving AF diagnosis and potentially reducing stroke risk in vulnerable populations.
- The EQUAL trial (NCT05686330) provides robust evidence for the clinical utility of wearable devices in cardiovascular screening.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Trial and Error and Algorithm

